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yoD and Myf5 are basic helix-loop-helix tran-
scription factors that play key but redundant
roles in specifying myogenic progenitors dur-
ing embryogenesis. However, there are functional differ-
ences between the two transcription factors that impact
myoblast proliferation and differentiation. Target gene
activation could be one such difference. We have used
microarray and polymerase chain reaction approaches
to measure the induction of muscle gene expression by
MyoD and Myf5 in an in vitro model. In proliferating
cells, MyoD and Myf5 function very similarly to activate
M
 
the expression of likely growth phase target genes such as
 
L-myc
 
, 
 
m-cadherin
 
, 
 
Mcpt8
 
, 
 
Runx1
 
, 
 
Spp1
 
, 
 
Six1
 
, 
 
IGFBP5
 
,
and 
 
Chrn
 
 
 
1
 
. MyoD, however, is strikingly more effective
than Myf5 at inducing differentiation-phase target genes.
This distinction between MyoD and Myf5 results from a
novel and unanticipated cooperation between the MyoD
NH
 
2
 
- and COOH-terminal regions. Together, these results
support the notion that Myf5 functions toward myoblast
proliferation, whereas MyoD prepares myoblasts for efﬁ-
cient differentiation.
 
Introduction
 
The process of skeletal muscle differentiation is orchestrated
by a family of four conserved basic helix-loop-helix (bHLH)
transcription factors that are collectively known as myogenic
regulatory factors (MRFs). Mice harboring single mutations of
either 
 
MyoD
 
 or 
 
Myf5
 
 are viable and do not have overt muscle
phenotypes, suggesting that MyoD and Myf5 have consider-
able overlap in their roles (Braun et al., 1992; Rudnicki et al.,
1992). However, either MyoD or Myf5 is required for proper
myogenesis during embryogenesis because compound 
 
MyoD
 
/
 
Myf5
 
-null mice lack essentially all skeletal muscle tissue at
birth (Rudnicki et al., 1993; Kassar-Duchossoy et al., 2004). In
contrast, myogenin is important for the terminal differentiation
and fusion of myoblasts into mature muscle fibers (Rawls et
al., 1998; Vivian et al., 2000). MRF4 appears to have a role as a
determination factor in a subset of myocytes in the early somite
and as a differentiation factor in later muscle fibers (Kassar-
Duchossoy et al., 2004).
Postnatal growth and regeneration of skeletal muscle is
mediated primarily by a pool of myogenic stem cells known as
satellite cells, which reside adjacent to the fibers. In response to
damage through injury or exercise, these satellite cells acti-
vate expression of MyoD and Myf5 and undergo numerous
rounds of proliferation as myoblasts. A small number of myo-
blasts return to a quiescent state, thus replenishing the pool of
satellite cells; the remainder continue their differentiation, fus-
ing into existing or new myofibers and expressing myogenin
and MRF4 while down-regulating Myf5. In contrast to wild-
type myoblasts, 
 
MyoD
 
-null myoblasts grow more quickly,
show aberrant expression of muscle markers, and differentiate
inefficiently (Sabourin et al., 1999), a phenotype that is the
cause of the regeneration deficit exhibited by compound dystro-
phic (
 
mdx
 
) 
 
MyoD
 
-null animals (Megeney et al., 1996). Con-
versely, 
 
Myf5
 
-null myoblasts proliferate poorly and differentiate
precociously (Montarras et al., 2000). The sequence of MRF
expression in activated satellite cells, in conjunction with the
phenotypes of single-null myoblasts and animals, argue that
MyoD and Myf5 do not have identical roles in myoblast prolif-
eration and induction of differentiation.
MyoD and Myf5 target genes have largely been examined
after the onset of differentiation and, hence, are involved in pro-
ducing the enormous phenotypic shift from a proliferating myo-
blast to a contractile, multinucleated muscle fiber. Although it
has been suggested that MyoD and Myf5 transactivation is
checked in growing myoblasts (whether by degradation [Thayer
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et al., 1989], modification [Lindon et al., 1998], signaling
[Vaidya et al., 1989; Li et al., 1992], or interfering heterodimer-
ization [Benezra et al., 1990]), the distinct phenotypic differ-
ences that are exhibited by growth phase 
 
MyoD
 
- and 
 
Myf5
 
-null
myoblasts suggest that MyoD and Myf5 do have active roles in
myoblasts. Indeed, Wyzykowski et al. (2002) identified 
 
Id3
 
 and
 
NP1
 
 as target genes of MyoD under growth conditions.
Distinguishing the distinct functions of MyoD and Myf5
is complicated by their abilities to auto- and cross-activate ex-
pression from the endogenous loci (Tapscott et al., 1988; Braun
et al., 1989; Thayer et al., 1989; Wyzykowski et al., 2002).
Such a circular network could account for the stabilization and
irreversibility of the commitment of a cell to a myogenic fate
(Thayer et al., 1989; Weintraub et al., 1991a). However, gene
expression changes resulting from the introduction of exoge-
nous MyoD or Myf5 could be an indirect effect that is mediated
through the other MRF. Expression of MyoD in the absence of
Myf5 (and vice versa) permits the comparative evaluation of
each factor’s functions in myogenic commitment.
To this end, we reintroduced MyoD or Myf5 into a
 
MyoD
 
 
 
/
 
Myf5
 
 double-null (double knockout [dblKO]) fibro-
blast cell line that was maintained in high serum growth condi-
tions. These cell lines are normally nonmyogenic but can be
converted to skeletal muscle upon the exogenous expression of
MyoD or Myf5. Microarray analysis identified numerous dif-
ferentially regulated genes, which were further validated by ex-
amining specific candidates using real-time PCR. A number of
growth phase targets were identified, demonstrating that MyoD
and Myf5 are transcriptionally active in proliferating cells.
Surprisingly, we did not find unique targets, and both MRFs
were able to induce the expression of these genes.
MyoD, however, was strikingly more effective at activat-
ing differentiation markers than Myf5. Additional support for
functional differences between MyoD and Myf5 were obtained
by using chimeric MRFs that interchanged their NH
 
2
 
-terminal,
bHLH, and COOH-terminal domains. The bHLH domains
(DNA binding and dimerization) are highly conserved between
the two genes, whereas their NH
 
2
 
- and COOH-terminal regions
are more divergent. Whereas Myf5 was inefficient at inducing
differentiation gene expression, the activation of a cohort
of these markers by the chimeric MRFs provided strong evi-
dence for cooperative gene activation by the NH
 
2
 
-terminal and
bHLH 
 
 
 
 COOH-terminal regions of MyoD. 
 
MyoD
 
-null pri-
mary myoblasts have a greatly reduced expression of the same
genes relative to wild-type myoblasts. Therefore, these data
support the idea that Myf5 is biased toward myoblast prolifera-
tion, whereas MyoD promotes myoblast differentiation (Sab-
ourin et al., 1999; Seale et al., 2001).
 
Results
 
MyoD and Myf5 activate skeletal muscle 
genes in growth conditions
 
To circumvent the potential problem of auto- and cross-activa-
tion by the primary myogenic factors (Braun et al., 1989; Thayer
et al., 1989; Weintraub et al., 1991b; Hollenberg et al., 1993),
we infected clonal double-null 
 
MyoD
 
 
 
/
 
 
 
;
 
Myf5
 
 
 
/
 
 
 
 (dblKO)
embryonic fibroblast lines with retrovirus expressing MyoD or
Myf5 or with empty control retrovirus. With this approach, we
were able to assess which genes were common targets of MyoD
and Myf5 versus those that could be uniquely regulated by one
or the other primary MRF. These genes could be directly acti-
vated by MyoD or Myf5 or could be indirectly activated through
an intermediate transcription factor; we considered both classes
to be downstream targets of the primary MRFs.
Shortly after infection of the dblKO target cells with retro-
virus, positive-expressing cells were purified by FACS based on
GFP fluorescence expressed from the bicistronic retroviral tran-
script (Fig. 1, A and B). Pools of 
 
 
 
10
 
6
 
 cells were then harvested
for total RNA after a further 24 h of culture in high serum growth
conditions. Fluorescently labeled probes generated from biologi-
cal–triplicate RNA samples were hybridized to MG-U74Av2
GeneChips, each containing probesets directed at 
 
 
 
6,000 genes
and an additional 
 
 
 
6,000 ESTs. Comparison of MyoD or Myf5
arrays with control arrays produced candidate lists that were con-
sidered to contain genes potentially regulated by MyoD or
Myf5 during growth phase (Table I and Table S1, available at
http://www.jcb.org/cgi/content/full/jcb.200502101/DC1).
MyoD expression in a 
 
MyoD
 
/
 
Myf5
 
 double-null back-
ground produced increases in 47 genes (including 
 
L-myc
 
 and
 
cadherin-15
 
), whereas only 17 genes were increased by Myf5.
Of these genes, 11 were common targets of both MyoD and
Myf5; eight were activated to similar degrees by both (
 
Chrn
 
 
 
1
 
,
 
Mcpt8
 
, 
 
Spp1
 
, 
 
Six1
 
, 
 
Runx1
 
, 
 
Idb2
 
, 
 
Ugcg
 
, and 
 
Kctd12
 
), whereas
the others were more strongly activated by MyoD (
 
IGFBP5
 
,
 
H19
 
, and 
 
 
 
-actin
 
). In contrast, only six genes were down-regu-
lated by either MyoD or Myf5 (none by both), and only four
had fold changes of 
 
  
 
2 (
 
Tcf20
 
, 
 
 
 
4.9; 
 
Dlk1
 
, 
 
 
 
2.9; 
 
Tgfbr3
 
,
 
 
 
2.7; and 
 
S100a13
 
, 
 
 
 
2.0). Relaxing the stringency of the se-
lection criteria had only a moderate effect, producing 70 in-
creases by MyoD and 32 increases by Myf5 versus 5 and 14
decreases, respectively (Tables S1–S4, available at http://
www.jcb.org/cgi/content/full/jcb.200502101/DC1).
One goal of our study was to identify targets that are
uniquely regulated by Myf5 but not by MyoD (and vice versa).
However, very few genes were suggested by the microarray
data to be increased by Myf5 and not by MyoD, and real-time
PCR directed at several of those transcripts, in turn, did not
support them as targets (
 
Skiip
 
, Table I; 
 
Refbp1
 
 and 
 
Snk
 
, unpub-
lished data). In contrast, 36 genes were up-regulated by MyoD
but not by Myf5. The majority of these targets (e.g., 
 
myogenin
 
,
 
myosin heavy chain
 
, and 
 
troponin-T
 
), however, are associated
with skeletal muscle differentiation.
At least six of the identified targets are transcription factors
(Table I) and may themselves regulate the expression of other
genes. Foremost amongst them is myogenin, which is an MRF
that is activated by MyoD immediately upon the switch to differ-
entiation conditions (Hollenberg et al., 1993; Bergstrom et al.,
2002). Therefore, we examined (by GeneChip analysis) the pos-
sibility that our candidates were activated indirectly by myogenin
using myogenin retrovirus–infected dblKO cells that were pre-
pared as for MyoD and Myf5. 50% (13/26) of myogenin targets
were also downstream from MyoD and Myf5. However, for most
nondifferentiation class genes, our microarrays indicated that tar- 
COOPERATION BETWEEN M
 
YO
 
D DOMAINS • ISHIBASHI ET AL.
 
473
 
All of the genes identified in Table I are robustly ex-
pressed by proliferating wild-type primary myoblasts (Fig. 2).
Most (47/53 
 
 
 
 89%) of these genes are decreased in 
 
MyoD
 
 
 
/
 
 
 
myoblasts, whereas the remainder (6/53) exhibit a mixture of
increase/no change/decrease calls and moderate fold increases.
Differentiation markers are vastly decreased (up to 140-fold for
 
myosin heavy chain-3
 
 or 
 
troponin T1
 
), whereas most putative
growth-phase genes showed only moderate changes (e.g., ap-
proximately eightfold for 
 
m-cadherin 
 
or 
 
L-myc 
 
and 
 
 
 
2.7–1.8-
fold for 
 
Six1
 
 or 
 
Runx1
 
).
Thus, in high serum conditions, MyoD and Myf5 are ca-
pable of regulating the transcription of numerous genes. The
growth phase regulation of a selection of those candidates was
then specifically examined.
 
Growth phase candidate validation by 
SYBR Green real-time PCR
 
The expression of these candidate genes was re-examined us-
ing a second set of independently derived RNA samples. This
second set was produced by the infection of a distinct dblKO
cell line with drug-selectable retrovirus, yielding proliferating
puromycin-resistant pools of cells that were expanded for 2 wk
under drug selection. SYBR Green real-time PCR was used to
quantitate target gene transcript levels using PCR primers that
were chosen to span at least one intron wherever possible. The
specificity of the PCR was verified by denaturing curve analysis
and direct sequencing of the products.
get activation was similar between MyoD, Myf5, and myogenin
treatments, which contrasts with the considerable induction of
myogenin by MyoD (10-fold) compared with Myf5 (1.2-fold;
Table I). This suggests that these genes are common targets of
MRFs rather than being strictly dependent on myogenin.
To identify potential growth phase targets of MyoD,
probable differentiation markers were removed using previous
work by Bergstrom et al. (2002). They used an inducible
MyoD–ER fusion system to examine gene expression by mi-
croarray analysis during early differentiation in low serum con-
ditions (Bergstrom et al., 2002). They identified nine subsets in
their data by using a clustering algorithm to find coordinate
patterns of temporal regulation, including those with transient
increases, early or delayed increases, and decreases in expres-
sion. Of the 571 genes identified by Bergstrom et al. (2002), we
mapped 298 to probesets on the MU74Av2 GeneChip on the
basis of GenBank, Unigene, or LocusLink IDs. Of these 298,
22 genes were also found to be up-regulated by MyoD in our
experiment, and an additional seven were also up-regulated by
Myf5. This provided added support to our data. A portion of
these genes fell within Bergstrom clusters 5 and 6 and primar-
ily represented differentiation-specific targets such as structural
genes (e.g., 
 
myosin
 
 and 
 
troponin
 
). However, others within clus-
ters 1–4 (early induction) and 7–9 (decreased expression
through differentiation) were also seen to have increased ex-
pression in our GeneChip data and were considered as possible
growth targets.
Figure 1. Preparation of RNA for GeneChip analysis. (A) Representative FACS plots of MyoD / ;Myf5 /  fibroblasts infected with retrovirus express-
ing MyoD, Myf5, or no gene as well as GFP from an internal ribosomal entry site (IRES) within the same transcript. GFP expression amongst sorted cells
after 24 h of culture was verified by fluorescence microscopy immediately before harvesting for total RNA. SSC, side scatter; FL1, fluorescence channel 1;
G, gate; R, region. The circled regions denote the sorted populations. Bar, 100  m. (B) Northern blot demonstrating equivalent levels of retroviral tran-
script expression amongst samples. (C) Western blots demonstrating robust MyoD or Myf5 expression in corresponding samples. 
JCB • VOLUME 171 • NUMBER 3 • 2005 474
 
Table I. 
 
Candidate MyoD/Myf5 target genes
     GeneChip (U74Av2) Real-time PCR
Fold
 
1
 
Call
 
2
 
Fold
 
3
 
Gene GenBank MyoD Myf5 Myogenin GFP MyoD Myf5
Transcription factors
 
Myogenin
 
X15784 10.1 1.2 2.8 A 27.0 8.4
 
Sine oculis–related homeobox 1
 
 (
 
Six1
 
) X80339 3.8 3.5 2.2 P/A 2.6 2.2
 
Inhibitor of DNA-binding 2
 
 (
 
Idb2
 
) AF077861 3.6 2.4 2.7 P   
Runt-related transcription factor 1 (Runx1) D26532 3.4 2.9 3.3 P/A 4.3 2.7
Hairy and enhancer of split 6 (Hes6) AW048812 2.7 0.9 1.1 A 1.3 1.0
Lung carcinoma myc-related oncogene 1 (L-myc)
4 X13945 2.3 1.5 0.8 A 4.7 2.6
Adhesion and receptors
Cholinergic receptor, nicotinic,  -1 M14537 24.6 16.0 15.8 A 5.0 6.1
Cholinergic receptor, nicotinic,   X03818 9.3 2.0 4.8 A 18.1 16.4
Cholinergic receptor, nicotinic,  -1 M17640 8.4 2.6 2.5 A 3.2 1.9
Cadherin 15 (m-cadherin)
4 AJ245402 4.2 0.5 1.9 A 290.6 85.4
Transmembrane 4 superfamily member 6 AF053454 2.6 2.3 2.5 P/A   
Discoidin domain receptor family, 1 L57509 2.3 1.6 2.6 A   
Secreted factors
Insulin-like growth factor–binding protein 5 L12447 142.6 9.8 7.0 A 123.1 89.0
Mast cell protease 8 (Mcpt8) X78545 11.7 11.1 14.4 A 6.2 15.6
Secreted phosphoprotein 1 (Spp1) X13986 8.3 5.7 4.6 P 11.5 18.5
ESTs
RIKEN cDNA 1190002N15 AW125453 5.0 1.7 2.9 P/A   
cDNA clone AW120874 3.2 1.3 1.9 P   
RIKEN cDNA 2610201A13 AA222883 1.4 2.1 1.2 P   
cDNA clone AA796831 1.1 2.1 1.7 P   
Others
H19 fetal liver mRNA X58196 35.6 6.1 13.7 P/M/A   
C1q/tumor necrosis factor-related protein 3
5 AI315647 5.8 1.9 3.1 P   
K  channel tetramerization domain 12
5 AI842065 4.9 6.0 3.2 P/A 1.1 1.3
Protein kinase inhibitor,   (Pkia) AW125442 4.6 1.6 2.1 A 1.8 1.0
UDP-glucose ceramide glucosyltransferase AI853172 4.3 3.3 2.9 P   
Paternally expressed 3 (Peg3) AF038939 3.6 1.0 1.9 P   
Enolase 3,   muscle X61600 3.5 1.8 2.0 P   
H2B and H2A histones X05862 3.3 0.6 1.7 A   
 -methylacyl-CoA racemase U89906 3.0 2.0 1.7 P/A   
Ankyrin repeat domain 1 (cardiac muscle) AF041847 3.0 3.0 3.1 P   
SH3 domain GRB2-like B1 (endophilin) AI842874 2.2 1.4 2.0 P   
WNT1-inducible signaling pathway 1 AF100777 2.2 2.3 2.6 P   
ADP ribosylation factor-like 6 interacting protein 5 AW049647 2.1 1.5 1.6 P   
SKI-interacting protein (Skiip) AW046671 1.2 4.8 3.6 P/A 1.0 0.5
Enabled homologue (Drosophila) D10727 1.9 2.4 2.9 P/A   
Differentiation markers
Actin,  , cardiac M15501 240.7 3.1 9.6 A 42.9 10.1
Troponin C, cardiac/slow skeletal M29793 172.8 9.3 16.8 A 1.8 1.0
Actin,  -1, skeletal muscle M12347 93.3 9.2 14.7 M/A 265.6 130.9
Troponin T3, skeletal, fast L48989 49.3 2.8 10.4 A   
Myosin light chain, phosphorylatable, fast skeletal AV290649 43.5 3.0 4.6 A 3850 1540.0
Myosin, light polypeptide 4 M19436 28.5 2.1 6.8 A   
Troponin T2, cardiac L47600 21.4 2.6 3.4 P/A   
Myosin, heavy polypeptide 3, skeletal M74753 17.0 0.8 2.0 A   
Troponin T1, skeletal, slow AV213431 16.4 0.8 0.8 A   
ATPase, Ca
2  transporting, cardiac fast 1 X67140 11.0 1.1 1.9 A   
Troponin I, skeletal, slow 1 AJ242874 10.5 0.9 2.7 A   
Myosin, light polypeptide 1 X12973 9.3 0.7 1.6 A   
Retinoblastoma 1 M26391 5.5 1.6 1.5 A   
Ryanodine receptor 1, skeletal muscle D38216 4.7 1.2 1.2 A   
Myosin-binding protein H U68267 3.9 0.5 1.5 A   
Sarcoglycan,   AB024921 3.5 1.0 1.8 A   
Myocyte enhancer factor 2A (MEF2A) AW045443 3.1 1.2 1.4 P/A 0.8 0.9
Growth arrest and DNA damage-inducible 45   U00937 2.5 0.9 1.1 P/A   
Cyclin-dependent kinase inhibitor 1A (P21) AW048937 2.2 1.1 1.0 P 1.4 1.4
1Mean fold change for pairwise comparisons of MyoD/Myf5/myogenin versus GFP from log(fold) change in MAS 5.0 software (Affymetrix, Inc.).
2Present/marginal/absent call from MAS 5.0.
3Fold change based on  Ct between MyoD/Myf5 versus puromycin alone real-time PCR, normalized to GAPDH expression.
4Added after manual inspection of dataset.
5C1q and K  channel identified in current annotations; previously listed as ESTs.COOPERATION BETWEEN MYOD DOMAINS • ISHIBASHI ET AL. 475
The majority of the genes that were selected as possible
growth phase target genes in the GeneChip data were also
found by real-time PCR to be up-regulated (Table I). The es-
timates of the fold up-regulation of Six1,  Runx1,  L-myc,
IGFBP5, and Mcpt8 were similar by either technique. Spp1
was increased more, and Chrn 1 was increased slightly less as
estimated by real-time PCR; nonetheless, each was signifi-
cantly increased by MyoD and Myf5. The increases in m-cad-
herin and myogenin levels by real-time PCR were much
greater than by microarray, probably as a result of the lower
background of the PCR assay. Again, however, the consis-
tency of the changes in target expression that were produced
by MyoD and Myf5 contrast with the variable induction of
myogenin by MyoD and Myf5, arguing that this is not a
strictly indirect effect.
Approximately one third of the candidates that were se-
lected for real-time PCR validation did not exhibit significant
changes in the stable pool samples (Table I). These genes
tended to be those that had modest fold changes in the Gene-
Chip data (e.g., Hes6, Pkia, Skiip, and p21). Probesets for dif-
ferentiation markers that exhibited larger changes by microar-
ray (such as cardiac troponin C and MEF2A) were likely seen
as a result of spontaneous differentiation in the original Gene-
Chip samples and were minimized in these proliferating cul-
tures. These observations support the conclusion that the stable
pools lacked the spontaneously differentiating cells that were
observed in our original samples.
Wyzykowski et al. (2002) used the same inducible MyoD
system as Bergstrom et al. (2002) to generate inputs for a repre-
sentational difference analysis protocol. They identified Id3
and NP1 as growth phase targets of MyoD (Wyzykowski et al.,
2002). Their cells were maintained in a high serum growth me-
dium during MyoD induction, suggesting that Id3 and NP1 are
not differentiation targets that are expressed simply as a conse-
quence of serum deprivation. Rather, they are induced in the
presence of cyclohexamide, indicating that they are likely to be
direct targets of MyoD that do not require intervening protein
synthesis for activation.
In contrast, our GeneChip experiments did not reveal an
induction of Id3 or NP1 in dblKO cells by either MyoD or
Myf5. To assess whether this was a consequence of low sensi-
tivity to those genes, we used SYBR Green real-time PCR to
specifically examine the expression of Id3 and NP1 in both the
GeneChip RNA samples and in RNA from drug-selected
pools; however, no significant changes were detected (unpub-
lished data). It is likely that these inconsistencies are attribut-
able to the numerous differences in our experimental systems,
including the method of MyoD expression, the type of host cell
used, and possibly the presence/absence of endogenous MyoD
and Myf5 genes.
From this combination of GeneChip and real-time PCR
analyses, we defined a validated set of growth phase targets.
Notably, MyoD and Myf5 were both capable of regulating
each of these genes, and none were strictly associated with one
MRF. These targets were then applied to examine the differ-
ences in function between corresponding regions of MyoD
and Myf5.
Association of growth phase gene 
activation with MyoD and Myf5 domains
Within their bHLH regions, Myf5 and MyoD exhibit 88%
identity and  95% homology at the amino acid level. In con-
trast, the regions that are NH2 and COOH terminal to this
highly conserved DNA-binding region exhibit considerably
more differences in sequence and function (Gerber et al.,
1997). Therefore, we hypothesized that functional differences
between MyoD and Myf5 would be a consequence of their
Figure 2. Decreased expression of differentiation markers by MyoD / 
primary myoblasts. Expression levels in MyoD-null primary myoblasts of the
genes in Table I show that the majority of differentiation markers are greatly
reduced relative to wild-type myoblasts (e.g., Myh3 to myogenin). In con-
trast, genes that are regulated in growth phase by MyoD and Myf5 are re-
duced to a lesser degree, if at all (e.g., Mcpt8, Six1, and Runx1). Calls are
shown for wild-type (n   3) or MyoD /  (n   3) myoblasts. P, present; M,
marginal; A, absent. Change calls are shown for nine pairwise compari-
sons between wild-type and MyoD /  myoblasts. I, increase; MI, mar-
ginal increase; NC, no change; MD, marginal decrease; D, decrease.JCB • VOLUME 171 • NUMBER 3 • 2005 476
divergent NH2- and COOH-terminal domains rather than a re-
sult of the bHLH recognition of discrete DNA sequences. To
test this, chimeric MRFs were built, interchanging the MyoD
and Myf5 NH2- and COOH-terminal regions around their
bHLH domains. This yielded six chimeric MRF genes (termed
d5d, d55, 55d, 5d5, 5dd, and dd5, where d denotes the portion
derived from MyoD and 5 denotes the portion derived from
Myf5) in addition to the full-length wild-type MyoD and Myf5
(Fig. 3 A).
Retrovirus expressing one of the chimeric MRFs were in-
troduced into dblKO fibroblasts, yielding drug-selected pools
of  10
5 clones from which RNA and protein were extracted
for analysis. The growth phase targets identified previously
were then assayed within these samples by SYBR Green real-
time PCR.
Both glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
transcript (input RNA quantity; reverse transcription) and MRF
protein levels (MRF expression) were used to enable equitable
comparisons by providing normalization between samples.
GAPDH transcripts were quantified by real-time PCR. Relative
protein expression levels of full-length and chimeric MRFs
were derived by direct digital densitometry of Western blots
probed with three primary antibodies that each recognized
unique but overlapping sets of four MRFs (Fig. 3 B). All of the
chimeras were demonstrated to be capable of regulating the
genes identified in the previous analysis, producing substantial
increases in expression compared with the puromycin-alone
negative control pool.
After normalization, 5dd tended to be the poorest relative
activator, whereas 55d was (in most cases) the best (Fig. 3 C).
However, in contrast to the other samples, these two chimeras
were subject to significant normalization corrections (Fig. 3 B),
which may have tended to overstate their effects. Nonetheless,
no single region of MyoD or Myf5 strictly correlated with en-
hanced or decreased relative activation. In certain cases (e.g.,
Chrn 1, m-cadherin, and Spp1), there is a tantalizing sugges-
tion that the Myf5 bHLH domain could have greater activity
than that of MyoD, although this pattern is not borne out
amongst the others. Chimeras dd5 and d55 have a greater effect
than MyoD or d5d. This might suggest that an interaction be-
tween the flanking portions of MyoD acts to suppress transac-
tivating activity, which is an effect that is disrupted when a
portion of Myf5 is substituted. A similar effect was observed in
deletion studies of MyoD (Weintraub et al., 1991b). Thus, for
growth-phase genes, the corresponding domains of MyoD and
Myf5 are otherwise interchangeable, and differences emerge
only with respect to the degree of target induction.
The MyoD NH2- and COOH-terminal 
domains cooperate to induce 
differentiation
A significant number of potential MyoD target genes that were
identified by GeneChip analysis were differentiation markers.
Wild-type MyoD and Myf5 and chimeras were expressed in
dblKO cells using retrovirus and were maintained for 3 d in
growth conditions before harvest. The proportion of infected
cells was very similar between pools (see Fig. 5 A). Differentia-
tion marker expression was examined by real-time RT-PCR
(Fig. 4 A). This set of vectors included a COOH-terminal FLAG
epitope tag that allowed for the normalization of gene expres-
sion against MRF protein levels (Fig. 4 B). Two growth phase
markers (Chrn 1 and Runx1, identified in the aforementioned
GeneChip experiment) showed little relative difference between
MyoD, Myf5, and the chimeras. In concordance with the Gene-
Figure 3. Gene expression induced by chi-
meras in growing dblKO cells. (A) Schematic
of MyoD/Myf5 chimeras. Chimeric MRFs
were constructed by interchanging the corre-
sponding NH2-terminal, bHLH-, and COOH-
terminal regions of MyoD and Myf5. (B) Levels
of MRF and tubulin protein expression in each
pool. The combination of three different
epitopes that were recognized by MyoD and
Myf5 antibodies was used to normalize the
expression results in C for relative MRF expres-
sion. Puro, puromycin-resistant empty vector
negative control. (C) Induction of transcripts
for potential growth phase targets by each of
MyoD, Myf5, and the chimeric MRFs (normal-
ized to MRF protein and GAPDH transcript
levels). Numbers on y axis indicates fold
changes.COOPERATION BETWEEN MYOD DOMAINS • ISHIBASHI ET AL. 477
Chip results, however, the expression of MyoD produced a con-
siderable activation of genes such as the cholinergic receptor  
and   subunits, myogenin,  -actin, myosin, and troponin (Fig. 4;
Table II shows unnormalized changes vs. empty vector con-
trols). In comparison, the level of Myf5 induction of these genes
was moderate relative to the empty vector control.
Substitution of the MyoD COOH terminus into Myf5
(55d) was not sufficient in growth phase to cause differentiation
and could produce only modest increases in the expression of
numerous differentiation markers. Replacement with the MyoD
NH2 terminus alone (d55) also resulted in just moderate gene in-
duction relative to full-length Myf5. Importantly, the concurrent
presence of MyoD NH2- and COOH-terminal regions (d5d) re-
sulted in activity approaching that of full-length MyoD.
The same pools of dblKO cells expressing one of the
wild-type or chimeric MRFs were challenged to differentiate
under reduced serum conditions. When the MyoD COOH ter-
minus was present (MyoD; d5d, 5dd, and 55d), there was en-
hanced differentiation compared with the corresponding Myf5
region (Myf5; dd5, d55, and 5d5; Fig. 5 B). Deletion of the pu-
tative cdk4-interacting domain (Zhang et al., 1999) from the
COOH-terminal region of full-length MyoD or insertion of
this region into the corresponding location of Myf5 does not
significantly affect these results based on protein (myosin
heavy chain immunostaining) or RNA (real-time PCR) mark-
ers (Punch, V., personal communication). The MyoD NH2 ter-
minus also had a noticeable effect on differentiation (Fig. 5 B,
compare MyoD with 5dd, d5d with 55d, dd5 with 5d5, and
d55 with Myf5). The MyoD bHLH domain, which has previ-
ously been connected to cell cycle arrest (Crescenzi et al.,
1990; Sorrentino et al., 1990), enhanced differentiation when
combined with the MyoD COOH-terminal region (Fig. 5 B,
compare MyoD with d5d and 5dd with 55d) but had little ef-
fect otherwise. Overall, the combined NH2- and COOH-terminal
portions of MyoD (MyoD and d5d) were most effective in
producing robust differentiation, whereas the two MRFs lack-
ing both (Myf5 and 5d5) were the poorest. Thus, in both
growth and differentiation conditions, the MyoD NH2- and
COOH-terminal regions cooperate to strongly activate the
myogenic differentiation program.
Discussion
Previous work has suggested that there are unique roles for
MyoD and Myf5 in adult myogenesis (Megeney et al., 1996;
Sabourin et al., 1999; Montarras et al., 2000). To investigate
the possibility that these phenotypes are a result of the activa-
tion of unique target genes by each of these transcription fac-
tors, we conducted genome-wide surveys of gene expression
changes in response to MRF expression. The embryonic fibro-
blast cells that were used are normally nonmyogenic but can
be converted to myoblasts by ectopic MRF expression. Im-
portantly, they were derived in a MyoD / ;Myf5 /  back-
ground, precluding cross-activation between MyoD and Myf5.
Figure 4. MyoD NH2 and COOH termini cooperate to activate differentiation marker expression. Amongst a variety of differentiation genes, the d5d chimera
had near wild-type activity, whereas the separated NH2 terminus and COOH terminus of MyoD had much less. In contrast, growth-phase genes Chrn 1
and Runx1 were induced similarly by MyoD, Myf5, and the chimeras. (A) Gene expression measured by real-time PCR and normalized to MRF protein
expression (B) and GAPDH transcript levels. Plotted as relative activity between MRFs. (B) Relative expression levels of FLAG-tagged chimeric MRFs in
growth phase (normalized to tubulin). Numbers on y axis indicate fold changes.JCB • VOLUME 171 • NUMBER 3 • 2005 478
Our microarray data indicates that MyoD expression in-
duces more myogenic genes than Myf5, often to a greater de-
gree. Comparison of our data with a previous study (Bergstrom
et al., 2002), however, demonstrated that the majority of these
MyoD-regulated targets are markers of differentiated skeletal
muscle. Thus, a unique function of MyoD (vs. Myf5) is a
strong ability to induce differentiation. MyoD-null primary myo-
blasts have vastly reduced levels of differentiation marker gene
expression (Fig. 2), which is consistent with the phenotypic
data on single-null primary myoblast cultures; in the absence of
MyoD, the myoblasts proliferate well and differentiate poorly
(Sabourin et al., 1999), whereas in the absence of Myf5, the op-
posite is true (Montarras et al., 2000). The moderate reduction
of levels of growth-phase genes in MyoD-null myoblasts likely
indicates a preference for activation by MyoD that Myf5 com-
pensates for only partially.
A previous study by Seale et al. (2004) used representa-
tion difference analysis to identify potential satellite cell mark-
ers and MyoD target genes using primary myoblasts from
MyoD /  mice as a model for early satellite cell activation.
The decreased expression of many genes (including Chrn ,
Chrn 1,  myogenin,  troponin T1,  H19, and Peg3) was seen
(Seale et al., 2004); these genes were up-regulated by MyoD
expression in our experiments, supporting the contention that
MyoD regulates these genes and promotes differentiation.
However, Seale et al. (2004) also showed that levels of numer-
ous genes (e.g., k-cadherin, integrin- 7, Plgf, VCAM1, Igsf4a,
Tcr v13, laminin  5, neuritin-1, and Klra18) are increased in
MyoD /  myoblasts, which express considerable Myf5. None
of these genes was identified in the current study as a Myf5 tar-
get. Thus, although MyoD and Myf5 have critical roles in the
myogenic program, other transcription factors (e.g., Pax3 or
Pax7) are likely needed to produce the full spectrum of normal
myoblast gene expression.
We initially focused on the genes that were activated in
the proliferating population by pruning our microarray results of
differentiation genes. To assist in this, we leveraged the work of
Bergstrom et al. (2002), who used an inducible MyoD in differ-
entiating dblKO cells. Their identified target genes were those
induced by serum deprivation, growth arrest, and MyoD activity
in the context of those conditions. However, their data also in-
cluded genes that are induced immediately before growth arrest
but remain up-regulated either as a result of a failure of their
RNA levels to decay to baseline during the early times of the ex-
periment or because expression continues in differentiation.
Thus, we identified a set of genes that were growth phase targets
of MyoD and Myf5. Furthermore, real-time PCR validation
confirmed that they were not unique targets but, rather, that they
all could be induced by either of these MRFs.
These similarities in function are perhaps not surprising.
Both MyoD- and Myf5-null mice possess grossly normal skeletal
muscle, indicating that there is redundancy and compensation for
the loss of either factor during development. Indeed, only with
the concurrent loss of MRF4 activity does the defect in skeletal
myogenesis become fully penetrant (Kassar-Duchossoy et al.,
2004). Therefore, rather than MyoD and Myf5 each having a
unique set of target genes that they are responsible for activating,
it is reasonable that these two factors are capable of regulating
the same downstream targets. Differences in MyoD and Myf5
function in proliferating cells may instead vary in the strength of
their effect on similar sets of genes. Whether MyoD and Myf5
function similarly during differentiation is a distinct question.
Previous work by Wyzykowski et al. (2002) suggested
that Id3 and NP1 were both activated by MyoD in myoblast
growth phase. Although our data does not show this, the dif-
ferences between our methods and theirs are considerable and
are more than adequate to explain the discrepancy. The cell
types in which the experiments were conducted are a primary
example: Wyzykowski et al. (2002) used 10t1/2 fibroblasts
(genetically wild type), whereas our fibroblasts were derived
from MyoD/Myf5 compound-mutant animals (it is also likely
that our cells have disrupted MRF4 function; Kassar-Duchos-
soy et al., 2004). It is quite conceivable that the presence
of other myogenic factors could be capable of modulating
MyoD activity.
An important conclusion to be drawn from these data
is that both MyoD and Myf5 are active transcription factors
in proliferating myoblasts (previously shown for MyoD by
Wyzykowski et al., 2002). Rather than passively awaiting a dif-
ferentiation signal, these two factors induce the expression of
myoblast growth-phase genes. MyoD and Myf5, therefore, act
not only to commit the cell to a myoblast identity but also to
prepare the myoblast for skeletal muscle differentiation.
The expression of MyoD or Myf5 led to the down-regula-
tion of only a very small number of genes. This could indicate
that they act primarily as transcriptional activators in high se-
rum conditions. However, our experimental system involved
converting a fibroblast cell type to the myogenic lineage and,
thus, was incapable of detecting MRF-mediated suppression of
any genes that were not initially expressed in the control cells.
Myogenin is not usually found in proliferating myoblasts
and is induced at the onset of differentiation (Hollenberg et al.,
1993; Weintraub, 1993; Bergstrom et al., 2002). The non-
differentiation targets that were assayed (e.g., Six1, Runx1,
Mcpt8, and Spp1) were induced to similar levels by either
MyoD or Myf5, whereas myogenin was induced strongly by
MyoD (10-fold) but only weakly by Myf5 (1.2-fold). Thus,
although myogenin can activate similar targets to MyoD (Wy-
zykowski et al., 2002) and Myf5 (Table I), indirect regula-
tion through myogenin is not dominant. The overexpression
Table II. Fold activation of myogenic genes by real-time PCR
1
Gene MyoD d5d 5dd 55d dd5 d55 5d5 Myf5 GFP
Actc1 89.2 68.5 6.5 7.8 8.9 7.6 2.8 2.5 1.0
Myogenin 145.0 114.8 17.4 14.5 26.2 18.4 3.7 7.4 1.0
Mylpf 2645.3 2727.9 249.2 356.0 211.1 234.3 62.4 81.8 1.0
Chrng 48.5 45.3 16.9 24.4 8.0 8.0 2.3 5.2 1.0
Acta1 35.4 21.8 7.7 16.1 5.7 10.8 6.9 5.6 1.0
ChrnA1 8.7 10.0 3.1 3.6 1.8 2.9 1.7 1.9 1.0
IGFBP5 127.4 104.0 104.0 91.4 74.2 35.9 22.8 23.0 1.0
Tncc 5.1 5.1 1.6 1.8 1.4 1.3 1.6 1.3 1.0
Chrnb1 11.7 14.9 10.2 11.2 6.7 8.8 7.1 7.7 1.0
Runx1 2.4 3.4 2.6 2.3 2.8 2.0 1.9 1.8 1.0
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of myogenin alone was much less effective than MyoD at in-
ducing differentiation marker transcripts, also demonstrating
that MyoD has distinct functions that are not simply conse-
quences of myogenin induction.
The high level of structural conservation between MyoD
and Myf5, particularly in the bHLH domain, provides a strong
rationale for our observation that there are few, if any, unique
growth phase target genes of MyoD or Myf5 (this might be ex-
tended to myogenin—the conserved bHLH domain may allow
the induction of growth targets, although myogenin would not
usually be found in growing cells). It has been shown previ-
ously that just three differing amino acids between the MyoD
and E12 bHLH regions encode specificity for the myogenic
program (Davis and Weintraub, 1992). However, our results
suggest that the three nonconservative and five conservative
amino acid substitutions between MyoD and Myf5 bHLH do-
mains are not likely to be involved in overt target gene selection,
although they could potentially provide sufficient variation for
more subtle types of regulation.
Chimeric MRFs, in which the NH2-, bHLH-, and COOH-
terminal domains of MyoD and Myf5 were interchanged, were
used to explore which portions of MyoD might provide for en-
hanced myogenic differentiation. Strikingly, only the d5d chi-
mera approached MyoD levels of differentiation gene expres-
sion, whereas the other chimeras, Myf5, and myogenin were
many times less effective. The MyoD NH2- and COOH-terminal
regions had much less activity when separated, thus indicating
a functional interaction between them.
In contrast to growth conditions (Fig. 4), differentiation
conditions allowed the MyoD NH2- and COOH-terminal re-
gions to function independently (Fig. 5, B and C), with the con-
current presence of both producing the greatest differentiation.
Therefore, each region is effective when growth signals are natu-
rally reduced under low serum conditions. However, cooperation
between these two MyoD regions was required to overcome the
strong growth signals that were provided by high serum medium.
Full-length MyoD, unlike Myf5, could, therefore, bias a cell
toward differentiation by sensitizing it to a moderate reduction
in growth signals.
Interestingly, the MyoD bHLH domain enhanced differ-
entiation at the molecular and phenotypic levels (Figs. 4 and 5),
but only when combined with the MyoD COOH terminus. De-
spite its exceptional similarity with the Myf5 bHLH, the MyoD
bHLH domain functionally differs in its interaction with the
MyoD COOH terminus. However, this MyoD bHLH effect
modulates gene expression levels rather than target gene selec-
tion (Fig. 4).
The NH2-terminal activity is likely to be the MyoD tran-
scriptional activation domain, which was previously mapped
between amino acids 3–56 (Weintraub et al., 1991b). It is inter-
esting to speculate that the COOH-terminal function is provided
by the chromatin remodeling amphipathic  -helix (helix III) do-
main that was previously described by Bergstrom and Tapscott
(2001). Whereas MyoD can induce muscle marker expression at
repressed loci, their studies demonstrated that a similar motif in
myogenin was ineffective at this task. This  -helix motif is con-
served in Myf5 (Gerber et al., 1997), but Myf5 is similar to myo-
genin in being less effective than MyoD at initiating muscle gene
expression. Thus, MyoD might be more efficient than Myf5 for
inducing differentiation because of a greater ability to remodel
chromatin at lineage-restricted loci. A similar domain appears in
MRF4 (Rhodes and Konieczny, 1989; Bergstrom and Tapscott,
2001) and could mediate the residual skeletal myogenesis that is
found in the absence of MyoD and Myf5 (Kassar-Duchossoy et
Figure 5. MyoD NH2 and COOH termini cooperatively
promote differentiation. The expression of MyoD/Myf5
chimeric MRFs that included the MyoD NH2- or COOH-
terminal regions in MyoD / ;Myf5 /  fibroblasts
produced more efficient differentiation in low serum con-
ditions than those with the corresponding Myf5 region.
(A) Percentage of infected cells in each pool based on
GFP expression immediately before differentiation. (B)
Percentage of total nuclei (n   1,000) found within a dif-
ferentiated myosin heavy chain  cell, normalized to A.
(C) Myosin heavy chain immunostaining of differentiated
pools (MF20, red; DAPI, blue). Bar, 100  m.JCB • VOLUME 171 • NUMBER 3 • 2005 480
al., 2004). Therefore, MyoD may use its COOH-terminal chro-
matin-remodeling domain to provide access to silenced muscle
genes for the NH2-terminal activation domain. In support of this,
the substitution of either portion alone into Myf5 produced only
moderate increases in gene expression, whereas together they
strongly activated a variety of differentiation markers (Fig. 4).
If MyoD is inclined to promote differentiation, whereas
Myf5 activates growth (but not differentiation) targets, then it
is consistent with their cell cycle regulation in growing myo-
blasts. MyoD levels peak at the differentiation checkpoint in
G1 of the cell cycle, whereas Myf5 levels are high in S/G2 and
G0 in association with proliferation and a failure to differenti-
ate (Kitzmann et al., 1998). This complementary pattern of ex-
pression allows for the maintenance of expression of growth-
phase genes and myogenic identity while ensuring that high
levels of MyoD occur only at a cell cycle point that is appro-
priate for differentiation.
That MyoD and Myf5 activate the same downstream tar-
get genes, but to differing degrees, does much to explain the
phenotypes observed in single knockout mice and cells. Our
data reinforce the partitioning of myogenic factors into primary
and secondary MRFs and, furthermore, add support to the con-
cept of a role for Myf5 in myoblast proliferation versus MyoD
instigating myogenic differentiation. MyoD’s ability to activate
differentiation marker expression despite the presence of high
levels of serum is a distinguishing biochemical function that is
not found in Myf5 and involves the cooperation of separate do-
mains of MyoD. These regions may allow MyoD to interact
with coactivators for which Myf5 has much less affinity. In the
future, studies to further understand the distinct roles played by
MyoD and Myf5 in growing and differentiating myoblasts, as
well as the structural constraints and intermolecular interac-
tions upon which those roles are built, will be essential to our
understanding of the mechanism by which damaged skeletal
muscle is efficiently regenerated.
Materials and methods
Cell culture
MyoD-null/Myf5-null dblKO mouse embryo fibroblasts were isolated, and
clonal lines were selected and expanded (designated 2C5/7 and 4C5/2).
Fibroblasts were cultured in subconfluent conditions in growth medium of
DME supplemented with 10% FCS and 1% penicillin/streptomycin. Prolif-
erating primary myoblasts from wild-type and MyoD /  mice were iso-
lated and cultured as described previously (Megeney et al., 1996; Sab-
ourin et al., 1999).
Myf5, MyoD, chimeric MRFs, or myogenin were introduced into
dblKO cells using retrovirus based on the three-plasmid HIT system (pro-
vided by V. Sartorelli, National Institutes of Health, Bethesda, MD; Sone-
oka et al., 1995), including expression plasmids based on the pHAN
backbone (with puromycin resistance driven from a distinct SV40 pro-
moter) or a modified pHAN backbone in which the puromycin cassette
was replaced by an internal ribosomal entry site and humanized Renilla
GFP (IRES-hrGFP) sequence (Stratagene). MRFs that were expressed using
the latter retroviral plasmid were COOH-terminally tagged with a 3 
FLAG epitope. Empty control virus expressed only puromycin resistance or
hrGRP. Retrovirus was produced by calcium phosphate transient cotrans-
fection of gag-pol (pHIT60), env (pHIT456), and expression (pHAN) plas-
mids into 293T cells; virus-containing medium was harvested 48 h from
the beginning of the transfection and was filtered through a 0.45- m sy-
ringe filter (Millipore). Cells were infected overnight with diluted, filtered
viral supernatant plus 8  g/ml polybrene (hexadimethrine bromide;
Sigma-Aldrich). Drug selection, where appropriate, was conducted with 1
 g/ml puromycin (Sigma-Aldrich) in growth medium for at least 1 wk; un-
infected controls were obliterated after 4–5 d of selection. Differentiation
was induced by replacing growth medium with DME   2% horse serum
(GIBCO BRL) and 1% penicillin/streptomycin.
FACS
3 d after infection with hrGFP-expressing retrovirus, pools of cells were
trypsinized, centrifuged, resuspended in PBS   5% FCS, filtered through a
MACS filter (Miltenyi Biotec) to remove aggregates, and placed on ice.
Cell sorting was performed using a MoFlo sorter (DakoCytomation), with
gating on hrGFP  populations set by a comparison with an uninfected
negative control pool. A small portion of the sorted cells was reanalyzed
to assess purity, and the remainder was replated in growth medium for an
additional 24 h before harvesting for total RNA.
RNA and protein isolation
Total RNA was purified using the RNeasy Mini Kit (QIAGEN) according
to the manufacturer’s instructions and quantitated by OD260 or by Ri-
boGreen (Invitrogen). RNA samples used for microarray analysis were
ethanol precipitated in order to reach a minimum concentration of 2  g/ml.
Protein extracts were made by lysis of pelleted cells in radioimmunopre-
cipitation assay (RIPA) lysis buffer supplemented with MiniComplete pro-
tease inhibitors (Roche).
Microarray analysis
Triplicate RNA samples for microarray analysis were submitted to the Ot-
tawa Genome Centre for hybridization to MG-U74Av2 GeneChips (Affyme-
trix, Inc.). Manufacturer’s quality controls were verified by the Centre. Raw
data files were processed with MicroArray Suite (MAS 5.0; Affymetrix, Inc.)
using the statistical algorithm (Affymetrix, Inc.) to derive signals and
present/marginal/absent calls for each sample; all possible pairwise com-
parisons were also performed between experimental and control replicates,
producing log(fold) ratio estimates of change and increase/no change/de-
crease calls. Processed results were then exported from MAS 5.0 and im-
ported into Excel and Access (Microsoft) for further manipulation. Probesets
showing consistent statistically significant changes between MRF and con-
trol samples were screened for detectable signal values (present/absent
calls) and absolute log(fold) changes of at least one. Probeset annotations
were obtained from http://www.affymetrix.com/analysis/index.affx. Mi-
croarray data is available from StemBase (http://www.scgp.ca:8080/
StemBase/; Ontario Genomics Innovation Centre; Perez-Iratxeta et al.,
2005) under experiments E223 (samples S361-4) and E59 (S78-9) and
from the National Center for Biotechnology Information’s Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/; Edgar et al., 2002; Barrett
et al., 2005) under series accession no. GSE3245 (GSM73053...64) and
GSE3244 (GSM73026, -29, -32, -35, -38, and -41).
Real-time PCR
RNA samples were reverse transcribed using random hexamer primers that
were included in the RNA PCR Core Kit (PerkinElmer) according to the man-
ufacturer’s instructions. Reverse transcription reactions were diluted (1:10 in
Fig. 3 C and 2:5 in Fig. 4 A) with 10 mM Tris, pH 8.0, yielding master
samples of reverse-transcribed products from which related PCR reactions
were drawn. Real-time PCR reactions included the following: 2  l of diluted
reverse transcription product, 10  l of 2  iQ SYBR Green SuperMix (Bio-
Rad Laboratories), 30 nM ROX passive reference dye (Stratagene), and 50
nM of each forward and reverse PCR primer. Real-time data was gathered
using a system (MX4000; Stratagene) over 40 cycles (30 s at 94 C, 60 s at
58 C, and 30 s at 72 C) followed by a denaturation curve from 54 to 94 C
in 30-s increments of 0.5 C to ensure amplification specificity. Ct values
were calculated with the MX4000 software by using moving window aver-
aging and an adaptive baseline. Fold changes, other calculations, and
chart plotting were performed in Excel. A PCR efficiency of 85% was as-
sumed. Primer sequences can be found in Table S2.
Chimeric MRF construction
Chimeric MyoD/Myf5 MRFs were created by using an overlapping PCR
approach to seamlessly fuse the NH2- and COOH-terminal regions to the
central bHLH domain (Fig. 3 A). The 318 aa of MyoD (available from
GenBank/EMBL/DDBJ under accession no. NM_010866) were divided
into aa 1–96 (NH2 terminus), 97–161 (bHLH), and 162–318 (COOH ter-
minus). The 255 aa of Myf5 (available from GenBank/EMBL/DDBJ under
accession no. NM_008656) were divided into aa 1–70 (NH2 terminus),
71–135 (bHLH), and 136–255 (COOH terminus). Each PCR product was
cloned into an appropriate expression plasmid and verified by sequenc-
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Immunocytochemistry and Western blot analysis
Primary antibodies that were used are listed as follows: mouse anti-FLAG
(M2 and M5; Sigma-Aldrich), rabbit anti-Myf5 (C-20; Santa Cruz Bio-
technology, Inc.), rabbit anti-MyoD (C-20; Santa Cruz Biotechnology,
Inc.), mouse anti-MyoD (5.2F; Sigma-Aldrich), mouse antimyogenin
(F5D) and mouse anti-myosin heavy chain (MF20; hybridoma superna-
tants), mouse antidesmin (D33; DakoCytomation), and mouse anti– -tubulin
(Sigma-Aldrich).
For immunostaining, cells were fixed with 4% PFA, permeabilized
with Triton X-100, and blocked with 5% normal goat serum in PBS. Primary
and secondary antibodies were applied in 5% goat serum–PBS. Secondary
detection used appropriate fluorescein- or rhodamine-conjugated antibod-
ies (Chemicon). 0.25  g/ml DAPI was included in a final wash step to
highlight nuclei. Samples were mounted in fluorescence mounting medium
(DakoCytomation), coverslipped, and imaged using a microscope (Axio-
phot 2; Carl Zeiss MicroImaging, Inc.), a 10  NA 0.30 plan-Neofluar
(Ph1;   /0.17) or 20  NA 0.75 plan Apochromat (  /0.17) objective,
and a digital camera (Axiocam; Carl Zeiss MicroImaging, Inc.). Digital
images were captured by using Axiovision (Carl Zeiss MicroImaging, Inc.)
and were processed with Photoshop (Adobe). Enumeration was assisted
by ImageJ software (http://rsb.info.nih.gov/ij/).
Western blots were made by electroblotting standard SDS-PAGE
gels onto Immobilon-P membranes. Membranes were blocked in 5%
skimmed milk in PBS; secondary detection was performed with an appro-
priate HRP-conjugated antibody (Bio-Rad Laboratories) visualized by ECL
(GE Healthcare). For densitometry, blots were digitally imaged with a 16-
bit GeneGnome chemiluminescence gel-doc system (Syngene), and bands
were quantified with the bundled GeneTools software (Syngene) except
parts of Fig. 3 B, for which the MyoD (C-20), Myf5 (C-20), and corre-
sponding tubulin (not depicted) blots were exposed to film, scanned, and
analyzed by using ImageJ software.
Online supplemental material
Tables S1–S4 show the expansion of Table I, where candidate gene lists
were derived by testing for consistent pairwise increase/decrease
changes (at least six of nine) as well as minimum mean threshold log(fold)
changes of  1 (twofold). Increases for MyoD, increases for Myf5, de-
creases for MyoD, and decreases for Myf5 correspond to Tables S1, S2,
S3, and S4, respectively. Table S5 shows the sequences and targets for
primers that were used for SYBR Green real-time PCR. Online supple-
mental material is available at http://www.jcb.org/cgi/content/full/
jcb.200502101/DC1.
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